Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis.
Patients undergoing chronic haemodialysis are at increased risk for infection with hepatitis B virus (HBV), but response to currently available vaccines is suboptimal. We undertook a 4-year prospective study of the efficacy of hepatitis B vaccine in patients with renal insufficiency, who were not yet dialysis-dependent. A booster dose of Recombivax HB was given at 3 or 4 years to those whose antibody levels fell below a predetermined point. Progression to dialysis was associated with poorer initial response to vaccination compared with those remaining dialysis-independent, but response to booster immunization was favourable in both groups. It is concluded that immunization of predialysis patients and subsequent booster vaccine results in a more favourable antibody response than has been seen historically in haemodialysis patients. Local endemicity and cost of vaccine should be considered when determining the best strategy for HBV immunization of patients with chronic renal failure.
Dukes
C S
CS
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Street
A C
AC
Starling
J F
JF
Hamilton
J D
JD
D015331:Cohort Studies; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000032:analysis / Q000096:biosynthesis; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications / Q000276:immunology; D012307:Risk Factors; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000627:therapeutic use*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D018074:Vaccines, Conjugate